Thermosensitive Polymeric Nanoparticles for Drug Co-Encapsulation and Breast Cancer Treatment

Vanessa Franco Carvalho Dartora,Julia S. Passos,Leticia V. Costa-Lotufo,Luciana B. Lopes,Alyssa Panitch
DOI: https://doi.org/10.3390/pharmaceutics16020231
IF: 6.525
2024-02-06
Pharmaceutics
Abstract:Despite advances in breast cancer treatment, there remains a need for local management of noninvasive, low-grade ductal carcinoma in situ (DCIS). These focal lesions are well suited for local intraductal treatment. Intraductal administration supported target site drug retention, improved efficacy, and reduced systemic exposure. Here, we used a poly(N-isopropyl acrylamide, pNIPAM) nanoparticle delivery system loaded with cytotoxic piplartine and an MAPKAP Kinase 2 inhibitor (YARA) for this purpose. For tumor environment targeting, a collagen-binding peptide SILY (RRANAALKAGELYKSILYGSG-hydrazide) was attached to pNIPAM nanoparticles, and the nanoparticle diameter, zeta potential, drug loading, and release were assessed. The system was evaluated for cytotoxicity in a 2D cell culture and 3D spheroids. In vivo efficacy was evaluated using a chemical carcinogenesis model in female Sprague–Dawley rats. Nanoparticle delivery significantly reduced the IC50 of piplartine (4.9 times) compared to the drug in solution. The combination of piplartine and YARA in nanoparticles further reduced the piplartine IC50 (~15 times). Treatment with these nanoparticles decreased the in vivo tumor incidence (5.2 times). Notably, the concentration of piplartine in mammary glands treated with nanoparticles (35.3 ± 22.4 μg/mL) was substantially higher than in plasma (0.7 ± 0.05 μg/mL), demonstrating targeted drug retention. These results indicate that our nanocarrier system effectively reduced tumor development with low systemic exposure.
pharmacology & pharmacy
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to develop a new method for local management of non - invasive, low - grade ductal carcinoma in situ (DCIS). Specifically, the researchers designed a thermosensitive polymer nanoparticle delivery system for co - encapsulating the cytotoxic drug piplartine and MAPKAP kinase 2 inhibitor (YARA), and treating breast cancer by intraductal administration in the breast. This delivery system aims to increase the retention time of drugs at the tumor site, enhance drug efficacy, and at the same time reduce systemic exposure and side effects. ### Research Background and Objectives - **Background**: Although progress has been made in breast cancer treatment, there is still a need for local management of non - invasive, low - grade ductal carcinoma in situ (DCIS). These focal lesions are suitable for local intraductal treatment. - **Objectives**: By designing a thermosensitive polymer nanoparticle delivery system, to achieve effective release of drugs at the tumor site, improve the local efficacy of drugs, and reduce systemic exposure and side effects. ### Key Technologies and Materials - **Nanoparticle Materials**: Poly (N - isopropylacrylamide) (pNIPAM) was used as the base material to prepare nanoparticles by copolymerizing acrylic acid (AAc) and 2 - acrylamido - 2 - methylpropanesulfonic acid (AMPS). - **Drugs**: The cytotoxic drug piplartine and MAPKAP kinase 2 inhibitor YARA. - **Targeting Peptide**: The collagen - binding peptide SILY (RRANAALKAGELYKSILYGSG - hydrazide) was used to modify the nanoparticles to improve their targeting ability in the tumor microenvironment. ### Experimental Methods 1. **Synthesis and Characterization of Nanoparticles**: - Hollow pNIPAM nanoparticles were synthesized by precipitation polymerization reaction, and AAc and AMPS were added to provide functionality and stability. - Transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used to characterize the size and ζ - potential of the nanoparticles. - The stability and degradation characteristics of the nanoparticles were verified by fluorescence labeling and degradation experiments. 2. **Drug Loading and Release**: - Piplartine and YARA were loaded into the nanoparticles, and the drug loading efficiency and release kinetics were determined by fluorescence and chromatography analysis. 3. **In vitro Experiments**: - **Cytotoxicity and Uptake**: The cytotoxicity and uptake of nanoparticles were evaluated in MCF - 7 and T47 - D breast cancer cell monolayers and spheroids. - **MK2 Inhibition**: The inhibitory effect of nanoparticles on the MK2 signaling pathway was detected by immunohistochemistry and ELISA. 4. **In vivo Experiments**: - **Tissue Retention**: The retention of nanoparticles in rat mammary tissue was monitored by fluorescence imaging. - **Efficacy Verification**: The in vivo efficacy of nanoparticles was evaluated using a chemical carcinogenesis model, and the change in tumor incidence was observed. ### Main Findings - **Cytotoxicity**: Nanoparticles significantly reduced the IC50 value of piplartine, and the combination of piplartine and YARA further enhanced cytotoxicity. - **In vivo Efficacy**: Nanoparticle treatment significantly reduced the incidence of tumors, and the drug concentration in mammary tissue was much higher than that in plasma, indicating a good local retention effect. ### Conclusion This study demonstrated an effective thermosensitive polymer nanoparticle delivery system, which can effectively treat breast cancer by intraductal administration, with the characteristics of low systemic exposure and high local efficacy. This strategy provides new possibilities for the local management of non - invasive breast cancer.